MDR1 and Cytochrome P450 Gene-Expression Profiles as Markers of Chemosensitivity in Human Chronic Myelogenous Leukemia Cells Treated with Cisplatin and Ru(III) Metallocomplexes
作者： Cesar Augusto Sam Tiago Vilanova-Costa , Hellen Karine Paes Porto , Lucas Carlos Gomes Pereira , Bruno Pereira Carvalho , Wagner Batista Dos Santos
DOI: 10.1007/S12011-014-0133-2
关键词: Immunology 、 Gene expression 、 Cisplatin 、 Leukemia 、 Caspase 3 、 Chronic myelogenous leukemia 、 Apoptosis 、 Population 、 Biology 、 Cancer research 、 Cancer
摘要: Leukemia is a major type of cancer affecting significant segment the population, and especially children. In fact, leukemia most frequent childhood cancer, with 26 % all cases, 20 mortality. The multidrug resistance phenotype (MDR) considered one causes failure in chemotherapy. present study aimed to investigate relationship between expression MDR1 CYP450 genes human chronic myelogenous cells (K-562) treated cisplatin (cisPt) two ruthenium-based coordinated complexes [cisCRu(III) cisDRu(III)]. tested compounds induced apoptosis K-562 tumor as evidenced by caspase 3 activation. Results also revealed that amplification P-gp gene greater exposed cisPt cisCRu(III) than cisDRu(III). Taken together, these results strongly demonstrate MDR-1 overexpression could be associated MDR phenotype, moreover, it contributing platinum structurally related compound, cells.
springer.com
sci-hub.se 参考文章(42)
Carla Silva Rodrigues Menezes, Luiz Carlos Gebrim de Paula Costa, Veridiana de Melo Rodrigues Ávila, Márcio José Ferreira, Carlos Ueira Vieira, Luis Alfredo Pavanin, Maria Inês Homsi-Brandeburgo, Amélia Hamaguchi, Elisângela de Paula Silveira-Lacerda, Analysis in vivo of antitumor activity, Cytotoxicity and Interaction between plasmid DNA and the cis-dichlorotetraammineruthenium(III) chloride Chemico-Biological Interactions. ,vol. 167, pp. 116- 124 ,(2007) , 10.1016/J.CBI.2007.02.003
E. Tanaka, Update: genetic polymorphism of drug metabolizing enzymes in humans. Journal of Clinical Pharmacy and Therapeutics. ,vol. 24, pp. 323- 329 ,(1999) , 10.1046/J.1365-2710.1999.00236.X
R.A. Alderden, H.R. Mellor, S. Modok, T.W. Hambley, R. Callaghan, Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug. Biochemical Pharmacology. ,vol. 71, pp. 1136- 1145 ,(2006) , 10.1016/J.BCP.2005.12.039
Stephen W. Fesik, Promoting apoptosis as a strategy for cancer drug discovery Nature Reviews Cancer. ,vol. 5, pp. 876- 885 ,(2005) , 10.1038/NRC1736
Michael W. N. Deininger, John M. Goldman, Junia V. Melo, The molecular biology of chronic myeloid leukemia Blood. ,vol. 96, pp. 3343- 3356 ,(2000) , 10.1182/BLOOD.V96.10.3343
G Sava, A Bergamo, Ruthenium-based compounds and tumour growth control (review). International Journal of Oncology. ,vol. 17, pp. 353- 418 ,(2000) , 10.3892/IJO.17.2.353
Dieter Runge, Christoph Köhler, Vsevolod E. Kostrubsky, Dana Jäger, Thomas Lehmann, Dorothee M. Runge, Ursula May, Donna Beer Stolz, Stephen C. Strom, Wolfgang E. Fleig, George K. Michalopoulos, Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochemical and Biophysical Research Communications. ,vol. 273, pp. 333- 341 ,(2000) , 10.1006/BBRC.2000.2902
Yoshiyuki Yamazaki, Ken-ichi Fujita, Kazuo Nakayama, Akihiro Suzuki, Katsunori Nakamura, Hiroshi Yamazaki, Tetsuya Kamataki, Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutation Research-genetic Toxicology and Environmental Mutagenesis. ,vol. 562, pp. 151- 162 ,(2004) , 10.1016/J.MRGENTOX.2004.06.003
Cesar Augusto Sam Tiago Vilanova-Costa, Hellen Karine Paes Porto, Flávia de Castro Pereira, Aliny Pereira de Lima, Wagner Batista Dos Santos, Elisângela de Paula Silveira-Lacerda, None, The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549) BioMetals. ,vol. 27, pp. 459- 469 ,(2014) , 10.1007/S10534-014-9715-X
Antoine Dorcier, Wee Han Ang, Sandra Bolaño, Luca Gonsalvi, Lucienne Juillerat-Jeannerat, Gàbor Laurenczy, Maurizio Peruzzini, Andrew D. Phillips, Fabrizio Zanobini, Paul J. Dyson, In Vitro Evaluation of Rhodium and Osmium RAPTA Analogues: The Case for Organometallic Anticancer Drugs Not Based on Ruthenium Organometallics. ,vol. 25, pp. 4090- 4096 ,(2006) , 10.1021/OM060394O